Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Anna P. Andreou"'
Autor:
Raffaele Ornello, Anna P. Andreou, Eleonora De Matteis, Tim P. Jürgens, Mia T. Minen, Simona Sacco
Publikováno v:
EBioMedicine, Vol 99, Iss , Pp 104943- (2024)
Summary: Migraine is a leading cause of disability worldwide. A minority of individuals with migraine develop resistant or refractory conditions characterised by ≥ 8 monthly days of debilitating headaches and inadequate response, intolerance, or co
Externí odkaz:
https://doaj.org/article/d58613bd500946509c4df158a26e2d39
Autor:
Thien Phu Do, Anna P. Andreou, Arao Belitardo de Oliveira, Robert E. Shapiro, Christian Lampl, Faisal Mohammad Amin
Publikováno v:
BMC Neurology, Vol 23, Iss 1, Pp 1-5 (2023)
Abstract Most individuals with access to the internet use social media platforms. These platforms represent an excellent opportunity to disseminate knowledge about management and treatment to the benefit of patients. The International Headache Societ
Externí odkaz:
https://doaj.org/article/0420963cab714516ab146a7b2470a9b0
Autor:
Aisha Zhantleuova, Charlotte Leese, Anna P. Andreou, Altynay Karimova, Guy Carpenter, Bazbek Davletov
Publikováno v:
Toxins, Vol 16, Iss 4, p 175 (2024)
This review discusses the expanding application of botulinum neurotoxin in treating neurological conditions. The article specifically explores novel approaches to using non-paralytic botulinum molecules. These new molecules, such as BiTox or el-iBoNT
Externí odkaz:
https://doaj.org/article/ab65cefcbc054cbc870d11c962d83ec5
Autor:
Anna P. Andreou, Matteo Fuccaro, Bethany Hill, Madeleine Murphy, Valeria Caponnetto, Rachael Kilner, Giorgio Lambru
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-9 (2022)
Abstract Background Controlled and real-world evidence have demonstrated the efficacy of calcitonin gene related peptide (CGRP) monoclonal antibodies (MABs) in migraine. However, data on the over-one-year sustained effectiveness of CGRP MABs in resis
Externí odkaz:
https://doaj.org/article/0585fd94935644d48509129b2bd79bd4
Autor:
Raffaele Ornello, Carlo Baraldi, Simona Guerzoni, Giorgio Lambru, Anna P. Andreou, Bianca Raffaelli, Astrid Gendolla, Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, Sabina Cevoli, Valentina Favoni, Fabrizio Vernieri, Claudia Altamura, Antonio Russo, Marcello Silvestro, Elisabetta Dalla Valle, Andrea Mancioli, Angelo Ranieri, Gennaro Alfieri, Nina Latysheva, Elena Filatova, Jamie Talbot, Shuli Cheng, Dagny Holle, Armin Scheffler, Tomáš Nežádal, Dana Čtrnáctá, Jitka Šípková, Zuzana Matoušová, Alfonsina Casalena, Maurizio Maddestra, Stefano Viola, Giannapia Affaitati, Maria Adele Giamberardino, Francesca Pistoia, Uwe Reuter, Simona Sacco
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-8 (2022)
Abstract Background Monoclonal antibodies acting on the calcitonin gene-related peptide (CGRP) or its receptor have changed migraine preventive treatment. Those treatments have led to reconsidering the outcomes of migraine prevention. Available data
Externí odkaz:
https://doaj.org/article/62e111c3fc11417ba73c91df8a1fe766
Publikováno v:
The Journal of Headache and Pain, Vol 21, Iss 1, Pp 1-10 (2020)
Abstract Background Clinical trials have shown the safety and clinical superiority of erenumab compared to placebo in chronic migraine (CM). The aim of this analysis is to evaluate the effectiveness and tolerability of erenumab in a real-world settin
Externí odkaz:
https://doaj.org/article/c5d43970fa5e4e6f9ac2fde43a6bf849
Autor:
Anna P. Andreou, Lars Edvinsson
Publikováno v:
The Journal of Headache and Pain, Vol 20, Iss 1, Pp 1-17 (2019)
Abstract Understanding the mechanisms of migraine remains challenging as migraine is not a static disorder, and even in its episodic form migraine remains an “evolutive” chronic condition. Considerable progress has been made in elucidating the pa
Externí odkaz:
https://doaj.org/article/18329b1eb3284f8e83c964e6f2d19ef5
Publikováno v:
Frontiers in Neurology, Vol 11 (2020)
Objective: Assessing the effects of caffeine withdrawal on migraine.Background: The effects of caffeine withdrawal on migraineurs are at large unknown.Methods: This was a randomized, double-blind, crossover study (NCT03022838), designed to enroll 80
Externí odkaz:
https://doaj.org/article/ee2e3c17b6854046842956f44d607b72
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 13 (2020)
Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) have been the first class of specifically developed preventive treatments for migraine. Clinical trials data suggest superiority of the CGRP mAbs to placebo in terms of prevention of
Externí odkaz:
https://doaj.org/article/cb2c3302f4a94a33bae4bcb78f2f440d
Autor:
Karl B. Alstadhaug, Anna P. Andreou
Publikováno v:
Frontiers in Neurology, Vol 10 (2019)
Background: The actions of caffeine as an antagonist of adenosine receptors have been extensively studied, and there is no doubt that both daily and sporadic dietary consumption of caffeine has substantial biological effects on the nervous system. Ca
Externí odkaz:
https://doaj.org/article/fb1f58c0d3f143668965740921c88b60